Adbry: animal efficacy model or human cells?

“The in vivo proof of principle experiments have been performed using models of type 2 immune responses mediated through signalling via IL-13. While some of the in vitro data suggest applicability of tralokinumab in treatment of AD, no relevant model of AD (e.g. ex vivo or in vitro human skin models) was presented in a proof of concept study.”

“Several of the models were performed in mice whereas previously discussed the endogenous mouse IL-13 is not bound by tralokinumab. For these studies, injection of human recombinant IL-13 was used since it can bind the mouse IL-13 receptor and mediate signalling in this manner, however, the activity of human IL-13 at the mouse receptor is less than that of mouse IL-13 at the same receptor.”

“The in vivo experiments are limited and were likely designed with an indication for the treatment of asthma, which was originally one of the clinical indications pursued for tralokinumab. Nevertheless, they do provide some limited evidence that the use of tralokinumab can modulate several aspects of a disease associated with a type II immune response.”